 Rebecca Rentea
Concepts (349)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hirschsprung Disease | 18 | 2024 | 56 | 8.890 |
Why?
| | Enterocolitis | 11 | 2024 | 36 | 6.730 |
Why?
| | Laparoscopy | 15 | 2022 | 219 | 4.060 |
Why?
| | Humans | 98 | 2024 | 6929 | 3.950 |
Why?
| | Colorectal Neoplasms | 9 | 2024 | 29 | 3.620 |
Why?
| | Retrospective Studies | 61 | 2024 | 1337 | 3.580 |
Why?
| | Postoperative Complications | 20 | 2024 | 202 | 3.280 |
Why?
| | Child | 61 | 2024 | 3348 | 3.140 |
Why?
| | Fecal Incontinence | 10 | 2023 | 20 | 3.080 |
Why?
| | Appendicitis | 6 | 2022 | 119 | 2.940 |
Why?
| | Alkaline Phosphatase | 7 | 2018 | 18 | 2.680 |
Why?
| | Infant | 38 | 2024 | 1449 | 2.470 |
Why?
| | Enterocolitis, Necrotizing | 8 | 2018 | 67 | 2.440 |
Why?
| | Specialties, Surgical | 3 | 2023 | 13 | 2.180 |
Why?
| | Infant, Newborn | 23 | 2024 | 826 | 2.120 |
Why?
| | Female | 43 | 2024 | 3534 | 2.100 |
Why?
| | Anal Canal | 15 | 2024 | 25 | 2.040 |
Why?
| | Male | 39 | 2024 | 3367 | 2.030 |
Why?
| | Botulinum Toxins | 4 | 2022 | 8 | 1.990 |
Why?
| | Appendectomy | 5 | 2022 | 103 | 1.870 |
Why?
| | Rectum | 14 | 2024 | 27 | 1.870 |
Why?
| | Child, Preschool | 30 | 2024 | 1562 | 1.770 |
Why?
| | Social Media | 2 | 2023 | 4 | 1.720 |
Why?
| | Digestive System Surgical Procedures | 7 | 2021 | 38 | 1.620 |
Why?
| | Constipation | 8 | 2024 | 15 | 1.530 |
Why?
| | Treatment Outcome | 23 | 2024 | 649 | 1.510 |
Why?
| | Ileum | 4 | 2016 | 15 | 1.420 |
Why?
| | Cloaca | 5 | 2022 | 6 | 1.330 |
Why?
| | Enema | 6 | 2024 | 15 | 1.320 |
Why?
| | Surgical Procedures, Operative | 2 | 2020 | 13 | 1.300 |
Why?
| | Pediatrics | 3 | 2024 | 183 | 1.290 |
Why?
| | Quality of Life | 8 | 2023 | 139 | 1.260 |
Why?
| | Adolescent | 18 | 2023 | 2183 | 1.260 |
Why?
| | Enteral Nutrition | 9 | 2023 | 65 | 1.190 |
Why?
| | Therapeutic Irrigation | 2 | 2024 | 10 | 1.160 |
Why?
| | Length of Stay | 7 | 2024 | 243 | 1.110 |
Why?
| | Perioperative Care | 3 | 2020 | 11 | 1.090 |
Why?
| | Rectal Fistula | 5 | 2023 | 6 | 1.040 |
Why?
| | Patient Discharge | 3 | 2020 | 61 | 1.020 |
Why?
| | Intestinal Mucosa | 2 | 2017 | 38 | 1.010 |
Why?
| | Cytokines | 4 | 2016 | 48 | 1.010 |
Why?
| | Rectal Prolapse | 3 | 2023 | 9 | 1.000 |
Why?
| | Animals | 11 | 2022 | 741 | 0.990 |
Why?
| | Cecostomy | 3 | 2024 | 3 | 0.960 |
Why?
| | Surgical Wound Infection | 5 | 2024 | 48 | 0.950 |
Why?
| | Intestines | 5 | 2018 | 28 | 0.940 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 38 | 0.930 |
Why?
| | Societies, Medical | 3 | 2024 | 50 | 0.910 |
Why?
| | Urethral Diseases | 2 | 2023 | 2 | 0.900 |
Why?
| | Colorectal Surgery | 5 | 2024 | 8 | 0.890 |
Why?
| | Colitis, Ulcerative | 1 | 2023 | 13 | 0.880 |
Why?
| | Fistula | 2 | 2020 | 2 | 0.860 |
Why?
| | Physicians | 2 | 2020 | 24 | 0.840 |
Why?
| | Clinical Competence | 3 | 2021 | 30 | 0.830 |
Why?
| | Young Adult | 8 | 2023 | 641 | 0.810 |
Why?
| | Rats | 8 | 2018 | 112 | 0.780 |
Why?
| | Neurotoxins | 1 | 2021 | 4 | 0.770 |
Why?
| | Lung Diseases | 2 | 2018 | 23 | 0.740 |
Why?
| | Colonic Diseases, Functional | 1 | 2020 | 1 | 0.740 |
Why?
| | Operating Rooms | 1 | 2020 | 6 | 0.730 |
Why?
| | Forecasting | 1 | 2020 | 24 | 0.730 |
Why?
| | Inpatients | 1 | 2020 | 43 | 0.720 |
Why?
| | Diagnostic Imaging | 2 | 2017 | 16 | 0.720 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 1 | 0.710 |
Why?
| | Surgical Flaps | 1 | 2019 | 9 | 0.710 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 57 | 0.710 |
Why?
| | Rats, Sprague-Dawley | 8 | 2018 | 47 | 0.680 |
Why?
| | Gastrostomy | 5 | 2022 | 67 | 0.680 |
Why?
| | Diverticulum | 1 | 2019 | 4 | 0.680 |
Why?
| | Isoenzymes | 1 | 2018 | 23 | 0.640 |
Why?
| | Pelvic Neoplasms | 1 | 2018 | 3 | 0.630 |
Why?
| | Organs at Risk | 1 | 2018 | 3 | 0.630 |
Why?
| | Fertility Preservation | 1 | 2018 | 7 | 0.630 |
Why?
| | Counseling | 1 | 2018 | 26 | 0.630 |
Why?
| | Infant, Premature, Diseases | 1 | 2018 | 23 | 0.620 |
Why?
| | Milk | 1 | 2017 | 6 | 0.620 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 3 | 0.620 |
Why?
| | Colostomy | 4 | 2023 | 6 | 0.620 |
Why?
| | Animals, Newborn | 7 | 2018 | 27 | 0.610 |
Why?
| | Lung | 2 | 2018 | 66 | 0.610 |
Why?
| | Dextrocardia | 1 | 2017 | 3 | 0.590 |
Why?
| | Infant Formula | 2 | 2018 | 16 | 0.590 |
Why?
| | Esophageal Perforation | 1 | 2017 | 4 | 0.580 |
Why?
| | Tracheoesophageal Fistula | 1 | 2017 | 27 | 0.580 |
Why?
| | Esophageal Atresia | 1 | 2017 | 33 | 0.580 |
Why?
| | Interleukin-23 | 1 | 2016 | 2 | 0.580 |
Why?
| | Interleukin-10 | 1 | 2016 | 5 | 0.570 |
Why?
| | Abnormalities, Multiple | 1 | 2017 | 36 | 0.570 |
Why?
| | Radiotherapy | 1 | 2016 | 5 | 0.560 |
Why?
| | Milk, Human | 1 | 2016 | 24 | 0.560 |
Why?
| | Mothers | 1 | 2016 | 33 | 0.560 |
Why?
| | Gastrointestinal Microbiome | 1 | 2016 | 8 | 0.560 |
Why?
| | Stress, Psychological | 1 | 2016 | 32 | 0.560 |
Why?
| | Quality Improvement | 2 | 2024 | 60 | 0.550 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2013 | 3 | 0.550 |
Why?
| | Adult | 6 | 2023 | 1199 | 0.550 |
Why?
| | Reoperation | 6 | 2024 | 64 | 0.550 |
Why?
| | Prospective Studies | 6 | 2023 | 547 | 0.540 |
Why?
| | Night Care | 1 | 2015 | 2 | 0.520 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 12 | 0.520 |
Why?
| | Clinical Clerkship | 1 | 2015 | 1 | 0.520 |
Why?
| | Coroners and Medical Examiners | 1 | 2015 | 1 | 0.520 |
Why?
| | Specialty Boards | 1 | 2015 | 1 | 0.520 |
Why?
| | General Surgery | 1 | 2015 | 19 | 0.510 |
Why?
| | Vagina | 4 | 2023 | 10 | 0.500 |
Why?
| | Internship and Residency | 1 | 2015 | 36 | 0.500 |
Why?
| | Surgical Wound Dehiscence | 2 | 2020 | 2 | 0.500 |
Why?
| | Follow-Up Studies | 7 | 2021 | 329 | 0.500 |
Why?
| | Real-Time Polymerase Chain Reaction | 5 | 2016 | 41 | 0.490 |
Why?
| | Pneumothorax | 3 | 2023 | 33 | 0.470 |
Why?
| | Lipopolysaccharides | 4 | 2016 | 20 | 0.460 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2013 | 1 | 0.460 |
Why?
| | Skin Transplantation | 1 | 2013 | 7 | 0.450 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 11 | 0.440 |
Why?
| | Transcription Factor RelA | 1 | 2012 | 2 | 0.440 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2024 | 41 | 0.440 |
Why?
| | Stress, Physiological | 1 | 2012 | 8 | 0.430 |
Why?
| | Wounds and Injuries | 1 | 2013 | 43 | 0.430 |
Why?
| | Intestinal Absorption | 1 | 2012 | 2 | 0.420 |
Why?
| | Pyloric Stenosis, Hypertrophic | 2 | 2023 | 23 | 0.420 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 81 | 0.400 |
Why?
| | Drug Evaluation, Preclinical | 4 | 2016 | 11 | 0.380 |
Why?
| | Hernia, Inguinal | 2 | 2021 | 32 | 0.380 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 275 | 0.380 |
Why?
| | Biomarkers | 3 | 2018 | 132 | 0.360 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 85 | 0.350 |
Why?
| | Urethra | 2 | 2019 | 5 | 0.340 |
Why?
| | Incidence | 3 | 2024 | 134 | 0.340 |
Why?
| | Recurrence | 4 | 2023 | 121 | 0.330 |
Why?
| | Constriction, Pathologic | 4 | 2024 | 21 | 0.330 |
Why?
| | Dilatation | 2 | 2024 | 3 | 0.290 |
Why?
| | Anus, Imperforate | 2 | 2024 | 4 | 0.270 |
Why?
| | United States | 3 | 2022 | 670 | 0.270 |
Why?
| | Neural Tube Defects | 2 | 2023 | 2 | 0.270 |
Why?
| | Tight Junctions | 2 | 2017 | 5 | 0.260 |
Why?
| | Permeability | 2 | 2017 | 7 | 0.260 |
Why?
| | Delayed Diagnosis | 1 | 2024 | 4 | 0.240 |
Why?
| | Ostomy | 1 | 2024 | 5 | 0.240 |
Why?
| | Decompression, Surgical | 1 | 2024 | 7 | 0.240 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 243 | 0.240 |
Why?
| | Gastroschisis | 1 | 2024 | 24 | 0.240 |
Why?
| | Bladder Exstrophy | 1 | 2023 | 1 | 0.230 |
Why?
| | Educational Status | 1 | 2023 | 21 | 0.230 |
Why?
| | Video Recording | 1 | 2023 | 15 | 0.230 |
Why?
| | Patient-Centered Care | 1 | 2023 | 16 | 0.230 |
Why?
| | Time Factors | 4 | 2024 | 263 | 0.230 |
Why?
| | Colitis | 1 | 2023 | 13 | 0.230 |
Why?
| | Urinary Fistula | 1 | 2023 | 1 | 0.230 |
Why?
| | Duodenal Obstruction | 1 | 2023 | 15 | 0.220 |
Why?
| | Spinal Dysraphism | 1 | 2023 | 8 | 0.220 |
Why?
| | Intestinal Atresia | 1 | 2023 | 19 | 0.220 |
Why?
| | Colectomy | 1 | 2023 | 13 | 0.220 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 19 | 0.220 |
Why?
| | Genitalia, Female | 1 | 2022 | 4 | 0.220 |
Why?
| | Abdominal Injuries | 1 | 2023 | 29 | 0.220 |
Why?
| | Limb Deformities, Congenital | 1 | 2022 | 2 | 0.210 |
Why?
| | Down Syndrome | 1 | 2023 | 39 | 0.210 |
Why?
| | Personal Satisfaction | 1 | 2022 | 10 | 0.210 |
Why?
| | Wounds, Nonpenetrating | 1 | 2023 | 62 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 96 | 0.210 |
Why?
| | Testicular Neoplasms | 1 | 2022 | 2 | 0.210 |
Why?
| | Botulinum Toxins, Type A | 1 | 2022 | 5 | 0.210 |
Why?
| | Cicatrix | 1 | 2021 | 5 | 0.200 |
Why?
| | Abdominal Cavity | 1 | 2021 | 1 | 0.200 |
Why?
| | Urinary Incontinence | 1 | 2021 | 3 | 0.200 |
Why?
| | Cryptorchidism | 1 | 2022 | 15 | 0.200 |
Why?
| | Masks | 1 | 2021 | 7 | 0.200 |
Why?
| | Hernia, Umbilical | 1 | 2021 | 15 | 0.200 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2021 | 27 | 0.200 |
Why?
| | Information Dissemination | 1 | 2021 | 8 | 0.200 |
Why?
| | Outpatients | 1 | 2021 | 28 | 0.200 |
Why?
| | Child, Hospitalized | 1 | 2021 | 26 | 0.200 |
Why?
| | Clinical Protocols | 2 | 2019 | 33 | 0.200 |
Why?
| | Social Support | 1 | 2021 | 26 | 0.190 |
Why?
| | Postoperative Period | 1 | 2021 | 18 | 0.190 |
Why?
| | Databases, Factual | 2 | 2024 | 108 | 0.190 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 16 | 0.190 |
Why?
| | Fundoplication | 2 | 2018 | 36 | 0.190 |
Why?
| | Risk Factors | 2 | 2023 | 490 | 0.190 |
Why?
| | Surgical Instruments | 1 | 2020 | 6 | 0.180 |
Why?
| | Cost Savings | 1 | 2020 | 10 | 0.180 |
Why?
| | Risk Assessment | 2 | 2018 | 136 | 0.180 |
Why?
| | Acute Disease | 2 | 2017 | 77 | 0.180 |
Why?
| | Appendix | 2 | 2018 | 11 | 0.180 |
Why?
| | Indocyanine Green | 1 | 2019 | 1 | 0.180 |
Why?
| | Probability | 1 | 2020 | 15 | 0.180 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 27 | 0.180 |
Why?
| | Replantation | 1 | 2019 | 1 | 0.180 |
Why?
| | Bayes Theorem | 1 | 2020 | 30 | 0.180 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 19 | 0.180 |
Why?
| | Telemedicine | 1 | 2021 | 59 | 0.180 |
Why?
| | Exanthema | 1 | 2019 | 4 | 0.170 |
Why?
| | Urogenital Abnormalities | 1 | 2019 | 12 | 0.170 |
Why?
| | Diarrhea | 1 | 2019 | 18 | 0.170 |
Why?
| | Parents | 1 | 2021 | 152 | 0.170 |
Why?
| | Nitric Oxide Synthase | 2 | 2016 | 6 | 0.170 |
Why?
| | Algorithms | 1 | 2020 | 108 | 0.170 |
Why?
| | Cystoscopy | 1 | 2019 | 1 | 0.170 |
Why?
| | RNA, Messenger | 2 | 2016 | 115 | 0.170 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 19 | 0.160 |
Why?
| | Thoracoscopy | 1 | 2018 | 29 | 0.160 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2018 | 3 | 0.160 |
Why?
| | Robotic Surgical Procedures | 1 | 2018 | 2 | 0.160 |
Why?
| | Neurogenic Bowel | 1 | 2018 | 3 | 0.160 |
Why?
| | Cesarean Section | 1 | 2018 | 3 | 0.160 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 43 | 0.160 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 7 | 0.160 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2018 | 4 | 0.160 |
Why?
| | Puberty | 1 | 2018 | 7 | 0.160 |
Why?
| | Hepatectomy | 1 | 2018 | 4 | 0.160 |
Why?
| | Suture Techniques | 1 | 2018 | 11 | 0.160 |
Why?
| | Malnutrition | 1 | 2018 | 8 | 0.160 |
Why?
| | Sutures | 1 | 2018 | 11 | 0.160 |
Why?
| | Hepatoblastoma | 1 | 2018 | 7 | 0.160 |
Why?
| | Embolization, Therapeutic | 1 | 2018 | 15 | 0.160 |
Why?
| | Evidence-Based Practice | 3 | 2023 | 17 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2018 | 16 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 122 | 0.160 |
Why?
| | Cytoprotection | 1 | 2017 | 1 | 0.160 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2017 | 1 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2018 | 41 | 0.150 |
Why?
| | Protein Isoforms | 1 | 2017 | 17 | 0.150 |
Why?
| | Missouri | 1 | 2018 | 77 | 0.150 |
Why?
| | Complementary Therapies | 1 | 2017 | 3 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2017 | 14 | 0.150 |
Why?
| | Dopamine | 1 | 2017 | 6 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2017 | 5 | 0.150 |
Why?
| | Intraoperative Care | 1 | 2017 | 8 | 0.150 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 12 | 0.150 |
Why?
| | Anticipation, Psychological | 1 | 2016 | 2 | 0.140 |
Why?
| | Postoperative Care | 1 | 2017 | 29 | 0.140 |
Why?
| | Cartilage Diseases | 1 | 2016 | 3 | 0.140 |
Why?
| | Joint Diseases | 1 | 2016 | 4 | 0.140 |
Why?
| | Ribs | 1 | 2016 | 6 | 0.140 |
Why?
| | Costal Cartilage | 1 | 2016 | 4 | 0.140 |
Why?
| | Fluorescent Antibody Technique | 2 | 2014 | 8 | 0.140 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 3 | 0.140 |
Why?
| | Mice | 1 | 2017 | 339 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 15 | 0.140 |
Why?
| | Down-Regulation | 1 | 2016 | 14 | 0.140 |
Why?
| | Up-Regulation | 1 | 2016 | 25 | 0.140 |
Why?
| | Esophageal Achalasia | 1 | 2016 | 3 | 0.140 |
Why?
| | Medical Errors | 1 | 2016 | 7 | 0.140 |
Why?
| | Disclosure | 1 | 2016 | 8 | 0.140 |
Why?
| | Funnel Chest | 1 | 2017 | 59 | 0.140 |
Why?
| | Workload | 1 | 2015 | 9 | 0.130 |
Why?
| | Work Schedule Tolerance | 1 | 2015 | 5 | 0.130 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 14 | 0.130 |
Why?
| | Operative Time | 3 | 2022 | 31 | 0.130 |
Why?
| | Pregnancy | 2 | 2015 | 212 | 0.130 |
Why?
| | Superoxides | 1 | 2014 | 4 | 0.130 |
Why?
| | Nitric Oxide | 1 | 2014 | 6 | 0.130 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 186 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 14 | 0.120 |
Why?
| | Disease Models, Animal | 1 | 2014 | 61 | 0.120 |
Why?
| | Registries | 2 | 2024 | 93 | 0.120 |
Why?
| | Hidradenitis Suppurativa | 1 | 2013 | 1 | 0.110 |
Why?
| | Abdominal Wound Closure Techniques | 1 | 2013 | 1 | 0.110 |
Why?
| | Wound Healing | 1 | 2013 | 8 | 0.110 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 7 | 0.110 |
Why?
| | Osteosarcoma | 1 | 2013 | 19 | 0.110 |
Why?
| | Comorbidity | 1 | 2013 | 56 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2013 | 25 | 0.110 |
Why?
| | Thoracotomy | 2 | 2023 | 19 | 0.110 |
Why?
| | Chest Tubes | 2 | 2023 | 24 | 0.110 |
Why?
| | Thoracic Surgery, Video-Assisted | 2 | 2023 | 18 | 0.110 |
Why?
| | Antibiotic Prophylaxis | 2 | 2024 | 31 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 24 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 36 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2012 | 47 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2012 | 17 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 50 | 0.110 |
Why?
| | Fluid Therapy | 2 | 2023 | 19 | 0.110 |
Why?
| | Hepatitis | 1 | 2012 | 1 | 0.110 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2012 | 1 | 0.110 |
Why?
| | Claudins | 1 | 2012 | 1 | 0.110 |
Why?
| | Claudin-1 | 1 | 2012 | 1 | 0.110 |
Why?
| | Claudin-3 | 1 | 2012 | 1 | 0.110 |
Why?
| | Dextrans | 1 | 2012 | 2 | 0.110 |
Why?
| | Models, Animal | 1 | 2012 | 10 | 0.110 |
Why?
| | Administration, Oral | 1 | 2012 | 58 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2012 | 53 | 0.100 |
Why?
| | Pneumonia | 1 | 2012 | 32 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 103 | 0.100 |
Why?
| | Laxatives | 2 | 2022 | 5 | 0.100 |
Why?
| | Herniorrhaphy | 2 | 2021 | 27 | 0.100 |
Why?
| | Urinary Bladder | 2 | 2021 | 7 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 47 | 0.080 |
Why?
| | Biopsy | 2 | 2018 | 63 | 0.080 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 5 | 0.060 |
Why?
| | Pelvis | 1 | 2024 | 4 | 0.060 |
Why?
| | Rectal Diseases | 1 | 2024 | 3 | 0.060 |
Why?
| | Feces | 1 | 2024 | 38 | 0.060 |
Why?
| | Colon | 1 | 2023 | 12 | 0.060 |
Why?
| | Administration, Intravaginal | 1 | 2023 | 3 | 0.060 |
Why?
| | Mesalamine | 1 | 2023 | 3 | 0.060 |
Why?
| | Anastomotic Leak | 1 | 2023 | 9 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2023 | 22 | 0.060 |
Why?
| | Spinal Cord | 1 | 2023 | 6 | 0.060 |
Why?
| | Rectovaginal Fistula | 1 | 2023 | 2 | 0.060 |
Why?
| | Biological Factors | 1 | 2023 | 1 | 0.060 |
Why?
| | Public Opinion | 1 | 2023 | 2 | 0.060 |
Why?
| | Arizona | 1 | 2023 | 9 | 0.060 |
Why?
| | Arkansas | 1 | 2023 | 9 | 0.060 |
Why?
| | Oklahoma | 1 | 2023 | 11 | 0.060 |
Why?
| | Texas | 1 | 2023 | 21 | 0.060 |
Why?
| | Injury Severity Score | 1 | 2023 | 63 | 0.050 |
Why?
| | Defecation | 1 | 2022 | 2 | 0.050 |
Why?
| | Spleen | 1 | 2023 | 32 | 0.050 |
Why?
| | Trauma Centers | 1 | 2023 | 44 | 0.050 |
Why?
| | Trachea | 1 | 2022 | 7 | 0.050 |
Why?
| | Spine | 1 | 2022 | 7 | 0.050 |
Why?
| | Abdomen | 1 | 2022 | 14 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 8 | 0.050 |
Why?
| | Orchiopexy | 1 | 2022 | 6 | 0.050 |
Why?
| | Electrolytes | 1 | 2021 | 13 | 0.050 |
Why?
| | Liver | 1 | 2023 | 130 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2021 | 16 | 0.050 |
Why?
| | Hospitals | 1 | 2021 | 36 | 0.050 |
Why?
| | Kidney | 1 | 2022 | 94 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2022 | 32 | 0.050 |
Why?
| | Testis | 1 | 2022 | 25 | 0.050 |
Why?
| | Perineum | 1 | 2021 | 3 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2021 | 44 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 333 | 0.050 |
Why?
| | Honduras | 1 | 2020 | 1 | 0.050 |
Why?
| | Hydrocolpos | 1 | 2019 | 1 | 0.040 |
Why?
| | Sacrum | 1 | 2019 | 2 | 0.040 |
Why?
| | Uterus | 1 | 2019 | 9 | 0.040 |
Why?
| | Toilet Training | 1 | 2019 | 1 | 0.040 |
Why?
| | Organ Size | 1 | 2018 | 14 | 0.040 |
Why?
| | Age Factors | 1 | 2019 | 211 | 0.040 |
Why?
| | Jejunum | 1 | 2018 | 3 | 0.040 |
Why?
| | Stomach | 1 | 2018 | 11 | 0.040 |
Why?
| | Portal Vein | 1 | 2018 | 8 | 0.040 |
Why?
| | Intubation, Gastrointestinal | 1 | 2018 | 19 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 130 | 0.040 |
Why?
| | Rupture | 1 | 2016 | 4 | 0.040 |
Why?
| | Syndrome | 1 | 2016 | 34 | 0.040 |
Why?
| | Surgeons | 1 | 2016 | 7 | 0.040 |
Why?
| | Global Health | 1 | 2016 | 14 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 24 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 36 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2015 | 10 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2014 | 4 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 22 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 72 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 85 | 0.030 |
Why?
| | Middle Aged | 1 | 2016 | 645 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|